

FACSIMILE TRANSMISSION

To: USPTO

Number: 571 273 8300

Pages: 13

Date: April 10, 2006

From: Karen DeBenedictis

RECEIVED
CENTRAL FAX CENTER

APR 10 2006

Customer No. 28880

CENTRAL FAX CENTER

Confirmation No. 4925

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/731,225

Filing Date December 9, 2003

First Named Inventor Charles Price Taylor, Jr., et al.

Art Unit 1614

Examiner Name Michael Grafteo

Attorney Docket Number PC25677A

ENCLOSURES (Check all that apply)

Fee Transmittal Form
 Fee Attached
 Amendment/Reply
 After Final
 Affidavits/declaration(s)
 Extension of Time Request
 Express Abandonment Request
 Information Disclosure Statement
 Certified Copy of Priority Document(s)
 Reply to Missing Parts/ Incomplete Application
 Reply to Missing Parts under 37 CFR 1.52 or 1.53

Drawing(s)
 Licensing-related Papers
 Petition
 Petition to Convert to a Provisional Application
 Power of Attorney, Revocation
 Change of Correspondence Address
 Terminal Disclaimer
 Request for Refund
 CD, Number of CD(s) _____
 Landscape Table on CD


After Allowance Communication to TC
 Appeal Communication to Board of Appeals and Interferences
 Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
 Proprietary Information
 Status Letter
 Other Enclosure(s) (please identify below):

Remarks

Authorization to charge the fee and any additional fees as necessary or credit any overpayment to deposit account 23-0455 is hereby given.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name Warner-Lambert Company, LLC

Signature 

Printed name Karen DeBenedictis

Date 4/10/06 Reg. No. 32,977

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature 

Typed or printed name Karen DeBenedictis

Date 4/10/06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

USPTO Fax No. 571-273-8300

PAGE 2/13 * RCVD AT 4/10/2006 9:01:01 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-3/14 * DNIS:2738300 * CSID:7346222928 * DURATION (mm:ss):03:16

BEST AVAILABLE COPY

**RECEIVED
CENTRAL FAX CENTER**

APR 10 2006

PC25677A

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT : Charles Price Taylor, Jr., et al. EXAMINER :

SERIAL NO. : 10/731,225 ART UNIT : 1614

FILED : December 9, 2003 PAPER NO. :

FOR : Alpha2delta ligands for the treatment of fibromyalgia and other disorders

Response Under 37 C.F.R § 1.111(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Office Action dated November 30, 2005.

Claims as previously presented are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 10 of this paper.